HTLV-1-induced cell fusion is limited at two distinct steps in the fusion pathway after receptor binding.
Human T-cell leukemia virus type 1 (HTLV-1) is notable among retroviruses for its poor ability to infect permissive cells, particularly as cell free virus. The virus is most efficiently transmitted between individuals by infected cells, where it is presumed that intracellular particles and viral RNA are transferred to target cells following fusion. Although the mandatory first step for HTLV-1 fusion is the binding of envelope SU (gp46) to the receptor, the events which follow this interaction and lead to fusion and infection have not been well characterized. To investigate these events, we studied two HTLV-1 chronically infected cell lines with different abilities to fuse with K562 target cells. Although not inherently fusion incompetent, the HTLV-1 envelope protein on MT2 cells was poorly able to undergo a change in membrane hydrophobicity required for fusion with the target cell membrane after binding to the receptor. High level expression of a fusion-competent HTLV-1 envelope protein on MT2 cells had little effect on improving this suggesting that the defect was encoded by the parent cell. Visible syncytia were seen after incubation of these cells with K562 target cells but complete fusion as measured by transfer of cellular contents into the recipient cell was not observed. In C91-PL cells, binding of SU to the receptor resulted in a sustained hydrophobic change of envelope accompanied by a cytopathic effect in mixed cell cultures and complete fusion. However, in C91-PL cells, overexpression of envelope protein blocked the transfer of cell contents after receptor engagement and initiation of cytopathic membrane changes, indicating that post binding fusion events were blocked. These data suggest that HTLV-1 fusion is a multistep process which is susceptible to inhibition at two seperate stages of the fusion pathway post receptor binding. This, and the inefficient infection by cell-free virions, may explain the poor infectivity of HTLV-1 in vivo and suggests strategies for preventative therapy.
Daenke
S
S
Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK. sdaenke@molbiol.ox.ac.uk.
Booth
S
S
D000818:Animals; D000911:Antibodies, Monoclonal; D002459:Cell Fusion; D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism / Q000821:virology; D015500:Chloramphenicol O-Acetyltransferase / Q000032:analysis / Q000235:genetics; D018920:Coculture Techniques; D003588:Cytopathogenic Effect, Viral; D005434:Flow Cytometry; D005453:Fluorescence; D015870:Gene Expression; D015686:Gene Products, env / Q000378:metabolism; D016356:Gene Products, tax / Q000378:metabolism; D017930:Genes, Reporter / Q000235:genetics; D015726:Giant Cells / Q000166:cytology* / Q000378:metabolism / Q000821:virology*; D015368:Human T-lymphotropic virus 1 / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D020014:K562 Cells; D051379:Mice; D011991:Receptors, Virus / Q000378:metabolism*; D015682:Retroviridae Proteins, Oncogenic / Q000378:metabolism
D000911:Antibodies, Monoclonal; D015686:Gene Products, env; D016356:Gene Products, tax; D011991:Receptors, Virus; D015682:Retroviridae Proteins, Oncogenic; C055266:gp46 protein, Human T-cell leukemia virus type I; D015500:Chloramphenicol O-Acetyltransferase